Open Label Randomized Phase II/III Trial of Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2018-2023

ABSTRACT

Open, randomized study of a trivalent dendritic cell therapy compared to standard therapy in primary treated patients with IDH wild-type, MGMT-promotor methylated glioblastoma. The IMP is dendritic cells transfected with mRNA of survivin, hTERT og autologous tumor stem cells derived from tumorspheres. Detailed Description Autologous leukapheresis for enrichment of PBMCs is performed after enrollment of the patient into the trial. Ex vivo generated DCs will be frozen and stored in the vapour phase of liquid nitrogen. At first surgery, tumor biopsies will be cultured under sphere-forming conditions under ex vivo conditions for enrichment of glioblastoma stem cells. mRNA will purified and amplified from these autologous tumor stem cells. At specified intervals patients randomized to the vaccine group will receive intradermal injections of DCs transfected with mRNA from autologous tumor stem cells, survivin and hTERT. Injections will be given as three separate injections at three separate sites. Vaccination will be continued for as long as there are vaccines available. More... »

URL

https://clinicaltrials.gov/show/NCT03548571

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Open, randomized study of a trivalent dendritic cell therapy compared to standard therapy in primary treated patients with IDH wild-type, MGMT-promotor methylated glioblastoma. The IMP is dendritic cells transfected with mRNA of survivin, hTERT og autologous tumor stem cells derived from tumorspheres.\n\nDetailed Description\nAutologous leukapheresis for enrichment of PBMCs is performed after enrollment of the patient into the trial. Ex vivo generated DCs will be frozen and stored in the vapour phase of liquid nitrogen. At first surgery, tumor biopsies will be cultured under sphere-forming conditions under ex vivo conditions for enrichment of glioblastoma stem cells. mRNA will purified and amplified from these autologous tumor stem cells. At specified intervals patients randomized to the vaccine group will receive intradermal injections of DCs transfected with mRNA from autologous tumor stem cells, survivin and hTERT. Injections will be given as three separate injections at three separate sites. Vaccination will be continued for as long as there are vaccines available.", 
    "endDate": "2023-05-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03548571", 
    "keywords": [
      "label", 
      "Phase II/III", 
      "dendritic cell", 
      "glioblastoma patient", 
      "DEN", 
      "randomized study", 
      "standard therapy", 
      "treated patient", 
      "IDH", 
      "Glioblastoma", 
      "Inosine Monophosphate", 
      "Messenger RNA", 
      "survivin", 
      "autologous tumor", 
      "leukapheresis", 
      "enrichment", 
      "PBMC", 
      "enrollment", 
      "patient", 
      "trial", 
      "ex vivo", 
      "vapor phase", 
      "liquid nitrogen", 
      "tumor biopsy", 
      "condition", 
      "vivo condition", 
      "glioblastoma stem cell", 
      "specified interval", 
      "vaccine", 
      "intradermal injection", 
      "DC", 
      "hTERT", 
      "injection", 
      "separate site", 
      "vaccination"
    ], 
    "name": "Open Label Randomized Phase II/III Trial of Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy (DEN-STEM)", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03548571"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00027.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.55325.34", 
        "type": "Organization"
      }
    ], 
    "startDate": "2018-04-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s00262-013-1453-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050979619", 
          "https://doi.org/10.1007/s00262-013-1453-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03548571"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03548571'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03548571'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03548571'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03548571'


 

This table displays all metadata directly associated to this object as RDF triples.

58 TRIPLES      16 PREDICATES      51 URIs      44 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03548571 schema:about anzsrc-for:3103
2 schema:description Open, randomized study of a trivalent dendritic cell therapy compared to standard therapy in primary treated patients with IDH wild-type, MGMT-promotor methylated glioblastoma. The IMP is dendritic cells transfected with mRNA of survivin, hTERT og autologous tumor stem cells derived from tumorspheres. Detailed Description Autologous leukapheresis for enrichment of PBMCs is performed after enrollment of the patient into the trial. Ex vivo generated DCs will be frozen and stored in the vapour phase of liquid nitrogen. At first surgery, tumor biopsies will be cultured under sphere-forming conditions under ex vivo conditions for enrichment of glioblastoma stem cells. mRNA will purified and amplified from these autologous tumor stem cells. At specified intervals patients randomized to the vaccine group will receive intradermal injections of DCs transfected with mRNA from autologous tumor stem cells, survivin and hTERT. Injections will be given as three separate injections at three separate sites. Vaccination will be continued for as long as there are vaccines available.
3 schema:endDate 2023-05-01T00:00:00Z
4 schema:keywords DC
5 DEN
6 Glioblastoma
7 IDH
8 Inosine Monophosphate
9 Messenger RNA
10 PBMC
11 Phase II/III
12 autologous tumor
13 condition
14 dendritic cell
15 enrichment
16 enrollment
17 ex vivo
18 glioblastoma patient
19 glioblastoma stem cell
20 hTERT
21 injection
22 intradermal injection
23 label
24 leukapheresis
25 liquid nitrogen
26 patient
27 randomized study
28 separate site
29 specified interval
30 standard therapy
31 survivin
32 treated patient
33 trial
34 tumor biopsy
35 vaccination
36 vaccine
37 vapor phase
38 vivo condition
39 schema:name Open Label Randomized Phase II/III Trial of Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy (DEN-STEM)
40 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03548571
41 schema:sdDatePublished 2019-03-07T15:27
42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
43 schema:sdPublisher N5752d37ebf9547a69706bbf1733c3fa5
44 schema:sponsor https://www.grid.ac/institutes/grid.55325.34
45 schema:startDate 2018-04-01T00:00:00Z
46 schema:subjectOf sg:pub.10.1007/s00262-013-1453-3
47 schema:url https://clinicaltrials.gov/show/NCT03548571
48 sgo:license sg:explorer/license/
49 sgo:sdDataset clinical_trials
50 rdf:type schema:MedicalStudy
51 N5752d37ebf9547a69706bbf1733c3fa5 schema:name Springer Nature - SN SciGraph project
52 rdf:type schema:Organization
53 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
54 rdf:type schema:DefinedTerm
55 sg:pub.10.1007/s00262-013-1453-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050979619
56 https://doi.org/10.1007/s00262-013-1453-3
57 rdf:type schema:CreativeWork
58 https://www.grid.ac/institutes/grid.55325.34 schema:Organization
 




Preview window. Press ESC to close (or click here)


...